Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018

References

• Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. Am J Manag Care. 2014;20(7 Suppl):S128–S135.
   PubMed Web of Science ®Google Scholar
• Tobón GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun. 2010;35:10–14.
   PubMed Web of Science ®Google Scholar
• England BR. Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016;68(1):36–45.
   PubMed Web of Science ®Google Scholar
• Krishnan E, Fries JF. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med. 2003;115(5):371.
   PubMed Web of Science ®Google Scholar
• Semerano L, Thiolat A, Minichiello E, et al. Targeting IL-6 for the treatment of rheumatoid arthritis: phase II investigational drugs. Expert Opin Investig Drugs. 2014;23(7).
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewè R, Breedveld FC, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. cited 2013 Oct 25. DOI:10.1136/annrheumdis-2013-204573
   Web of Science ®Google Scholar
• Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10(42):iii-iv, xi-xiii, 1–229.
   PubMed Web of Science ®Google Scholar
• Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford). 2012;51(Suppl 5):v22–v30.
   PubMed Web of Science ®Google Scholar
• Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537–3545.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Devogelaer JP, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784–788.
   PubMedGoogle Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(11):1653–1661.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Amano K, et al. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Mod Rheumatol. 2014;24(3):399–404.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2(4):288–294.
   PubMed Web of Science ®Google Scholar
• Hou T, Tieu BC, Ray S, et al. Roles of IL-6-gp130 signaling in vascular inflammation. CurrCardiol Rev. 2008;4(3):179–192.
   Google Scholar
• Fonseca JE, Santos MJ, Canhão H, et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538–542.
   PubMed Web of Science ®Google Scholar
• Hibi M, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149–1157.
   PubMed Web of Science ®Google Scholar
• Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8:241–252.
   PubMedGoogle Scholar
• Rose-John S, Neurath MF. IL-6 trans-signaling: the heat is on. Immunity. 2004;20:2–4.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010;184:1543–1551.
   PubMed Web of Science ®Google Scholar
• Nowell MA, Richards PJ, Horiuchi S, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130J. Immunol. 2003;171:3202–3209.
   Web of Science ®Google Scholar
• Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491–501.
   PubMed Web of Science ®Google Scholar
• Mihara M, Hashizume M, Yoshida H, et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. ClinSci (Lond). 2012;122(4):143–159.
   PubMed Web of Science ®Google Scholar
• Lazzerini PE, Capecchi PL, Guidelli GM, et al. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date. Drug Des Devel Ther. 2016;10:3083–3098.
   PubMed Web of Science ®Google Scholar
• Nishimoto N. Interleukin-6 in rheumatoid arthritis. CurrOpin Rheumatol. 2016;18:277–281.
   Google Scholar
• Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521–1529.
   PubMed Web of Science ®Google Scholar
• Madhok R, Crilly A, Watson J, et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232–234.
   PubMed Web of Science ®Google Scholar
• Uson J, Balsa A, Pascual-Salcedo D, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol. 1997;24:2069–2075.
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425–4433.
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Stroes ES. The interleukin-6 pathway and atherosclerosis. Lancet. 2012;379(9822):1176–1178.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, et al.. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.
   Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention ofstructural joint damage at one year. Arthritis Rheum. 2011;63(3):609–621.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–2829.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, Van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–2980.
   PubMed Web of Science ®Google Scholar
• Strand V, Burmester GR, Ogale S, et al. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford). 1860–69;51(10):2012.
   Google Scholar
• Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116:3627–3634.
   PubMed Web of Science ®Google Scholar
• Protogerou AD, Zampeli E, Fragiadaki K, et al. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011;219(2):734–736.
   PubMed Web of Science ®Google Scholar
• Genovese MC. Sarilumab Plus Methotrexate in Patients With Active RheumatoidArthritis and InadequateResponse to Methotrexate: results of a Phase III Study. Arthritis Rheumatol. 2015;67(6):1424–1437.
   PubMed Web of Science ®Google Scholar
• Van Roy M. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoidarthritis. Arthritis Res Ther. 2015;17:135.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phaseIIb, randomized, double-blind,placebo/active-controlled, dose-rangingstudy. ArthritisRheumatol. 2015;67(10):2591–2600.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014;73:1607–1615.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Mola EM. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014;73:9.
   Web of Science ®Google Scholar
• Reference ID: 4101431. [cited 2017 Nov 15]. Available from: https://www.accessdata.fda.gov
   Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial [abstract]. Arthritis Rheumatol. 2016;68(suppl 10).
   Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006.
   PubMed Web of Science ®Google Scholar
• Galeotti C, Boucheron A, Guillaume S, et al. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody. MolCancerTher. 2012;11(8):1623–1626.
   Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. ArthritisRheum. 2010;62(2):542–552.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford). 2009;48(4):347–354.
   PubMed Web of Science ®Google Scholar
• Lin P. Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015;9:1697–1702.
   PubMed Web of Science ®Google Scholar
• Sun Y, Hsu B, Wang D, et al. Improvement in measures of depressed mood and anhedonia in two randomized, placebo-controlled phase III studies of sirukumab, a human anti-interleukin-6 antibody, in patients with rheumatoid arthritis. Presented at: European League Against Rheumatism (EULAR) Congress; 2017 Jun 14–17; Madrid, Spain. 2017. doi:10.1136/annrheumdis-2017-eular.3263.
   Google Scholar
• Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011;72:270–281.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, De Vries DE, Marciniak SJ, et al. Absolute bioavailability and pharmacokinetic comparability of sirukumab following subcutaneous administration by a prefilled syringe or an autoinjector. Clin Pharmacol Drug Dev. 2016.
   Web of Science ®Google Scholar
• Smolen JS, Weinblatt ME, Sheng S, et al. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:1616–1625.
   PubMed Web of Science ®Google Scholar
• Takeuchi T. Sirukumab for rheumatoidarthritis: the phase III SIRROUND-D study. AnnRheumDis. 2017;76(12):2001–2008.
   PubMed Web of Science ®Google Scholar
• Janssen Research and Development. A study of CNTO 136 (Sirukumab), a human Anti-IL-6 monoclonal antibody, administered subcutaneously, in patients with active rheumatoid arthritis despite Anti-TNF-Alpha therapy (SIRROUND-T). NLM identifier: NCT01606761. [cited 2017 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01606761?term=SIRROUND-T&rank=2
   Google Scholar
• Aletaha D, Bingham CO, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomized, double-blind, placebo-controlled, parallel group, multinational, phase 3 study. Lancet. 2017;389:1206–1217.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Van Adelsberg J, Lin Y, et al. Sarilumab and non-biologic disease-modifying antirheumatic drugs in patients with active RA and inadequate response or intolerance to TNF inhibitors. ArthritisRheumatol. 2017;69:277–290.
   PubMed Web of Science ®Google Scholar
• Taylor PC Efficacy and safety of monotherapy with sirukumab, an anti–IL-6 cytokine monoclonal antibody, compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis: results of a global, randomized, double-blind, parallel-group. Phase 3 Study. 2016 ACR/ARHP Annual Meeting ABSTRACT NUMBER: 3222.
   Google Scholar
• Janssen Research and Development. A study comparing sirukumab (CNTO 136) monotherapy with adalimumab (HUMIRA®) monotherapy in the treatment of active rheumatoid arthritis (SIRROUND-H). NLM identifier: NCT02019472. [cited 2017 Nov 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02019472?term=SIRROUND-H&rank=1
   Google Scholar
• Clinicaltrial.gov. A study of CNTO 136 (Sirukumab) administered subcutaneously in Japanese patients with active rheumatoid arthritis unresponsive to Methotrexate or Sulfasalazine. NCT01689532.
   Google Scholar
• Janssen Development and Research. Long-term safety and efficacy of sirukumab in participants with RA completing studies CNTO136ARA3002 or CNTO136ARA3003 (SIRROUND-LTE). clinicaltrials.gov/ct2/show/NCT01856309?term=NCT01856309& rank=1. NLM identifier: NCT01856309. Accessed 2016 Aug 9.
   Google Scholar
• Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626–1634.
   PubMed Web of Science ®Google Scholar
• Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71:1183–1189.
   PubMed Web of Science ®Google Scholar
• Mackey RH, Kuller LH, Deane KD, et al. Rheumatoid Arthritis, anti-CCP positivity and cardiovascular disease risk in the women’s health initiative. Arthritis Rheumatol. 2015;67(9):2311–2322.
   PubMed Web of Science ®Google Scholar
• Pujades-Rodriguez M, Duyx B, S L T, et al. Rheumatoid Arthritis and incidence of twelve initial presentations of cardiovascular disease: a population record-linkage cohort study in England. PLoS One. 11(3):e0151245
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden cardiac deaths in Rheumatoid Arthritis. A population- based cohort study. Arthritis Rheum. 2005;52(2):402–411.
   PubMedGoogle Scholar
• Hagiwara Y, Miyoshi S, Fukuda K, et al. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent ICAL, [Ca+2]i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol. 2007;43:710–716.
   PubMed Web of Science ®Google Scholar
• Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2017;38:1717–1727.
   PubMed Web of Science ®Google Scholar
• Adlan AM, Panoulas VF, Smith JP, et al. Association between corrected QT interval and inflammatory cytokines in Rheumatoid Arthritis. J Rheumatol. 2015;42:3.
   Web of Science ®Google Scholar
• Lazzerini PE, Acampa M, Capecchi PL, et al. Antiarrhythmic potential of anticytokine therapy in Rheumatoid Arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation. Arthritis Care Res (Hoboken). 2015;67(3):332–339.
   PubMed Web of Science ®Google Scholar
• Pincus T, Sokka T. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?. Ann Rheum Dis. 2004;63(suppl2):ii32–ii39.
   PubMedGoogle Scholar